

West Virginia Medicaid Drug Utilization Review Board Minutes February 15, 2023

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpenng, PharmD, PhD, Chair
David Gloss, MD, Vice Chair
Chris Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
Lester Labus, MD
Ernest Miller, DO
C.K. Babcock, PharmD

Members Absent:

Mary Nemeth-Pyles, MSN, RN, CS
K.C. Lovin, PA-C
Michael Ballow, PharmD
Michael Lonsinger, PharmD

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, Director of Pharmacy Services
Priya Shah, PharmD, Drug Utilization Review Coordinator
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Data Analyst
Gail Goodnight, RPh, Rebate Manager

Contract Staff:

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)
Cory Chambliss, Kepro
Scott Donald, PharmD, Kepro
Alena Mitchell PharmD, Kepro
Eric Sears, RPh, Gainwell
Jeffrey Barkin, MD – Change Healthcare
Joe Bergondo, PharmD – Change Healthcare

1. INTRODUCTIONS

- a. Chris Terpenng, Chair, welcomed everyone to the Board meeting at 3:04 pm EST. The DUR Board and others introduced themselves.

2. APPROVAL OF MINUTES FROM November 16th, 2022 DUR BOARD MEETING

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

3. **OLD BUSINESS**

- a. None

4. **NEW BUSINESS**

a. **Speakers**

- i. None

b. **Updates from January 25th, 2023 P&T Committee Meeting**

- i. Dr. Joe Bergondo presented the PDL status updates from the January 25, 2022 P&T meeting.

c. **Prior Authorization Criteria.** Attachment A

- i. **Antipsoriatics, topical:** approved as presented.
- ii. **Auvelity:** approved as presented.
- iii. **Zonisade:** approved as presented.
- iv. **Ryaltris:** approved as presented.
- v. **Tadliq:** approved as presented.
- vi. **Entadfi:** approved as presented.

5. **REPORTS – 4th Quarter of 2022**

- a. **Gainwell Technologies Quarterly Report:** Mr. Eric Sears presented an overview of the 2022 Fourth Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the Fourth Quarter of 2022. Attachment C
- c. **Kepro:** There was no report for retro DUR, the lock in program, or the number of letters sent/returned for the Fourth Quarter of 2022, as Kepro's contract began this quarter. Dr. Alena Mitchell requested the Board rank the 5 topics for population-based interventions. Attachment D

6. **OTHER BUSINESS**

- a. None

7. **NEXT MEETING AND ADJOURNMENT**

- a. The meeting concluded at 4:05 pm EST.
- b. The next meeting will be May 24th, 2023, from 4-6pm (EST) on a virtual platform.